Feldan Therapeutics Partners with TransBIOTech for an NSERC-Funded Project
Feldan Therapeutics is collaborating with TransBIOTech on a project funded by NSERC with up to $450,000 to accelerate the development of innovative intralesional treatments. This non-dilutive funding will support Feldan's three-year development of novel therapeutic approaches targeting tumor lesions through intralesional injections. TransBIOTech will undertake the necessary in vivo experiments to advance this research.
Evaluate and Demonstrate the Efficacy of Probiotics
Assessing the efficacy of probiotics cannot be confined to a single test or an isolated model. An integrated approach, combining relevant in vitro and in vivo assays, not only facilitates a deeper understanding of the specific mechanisms of action of the strains but also enables the selection of the most promising candidates from the upstream development phases.
Biena and TransBIOTech Secure a $300,000 Grant
This collaboration aims to advance population health, reduce healthcare costs, and reinforce Canada's leadership in microbiome-based innovation.
